Search filters

List of works by Anas Younes

ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

scientific article published on 06 September 2018

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 15 February 2019

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

scientific article published on 10 December 2017

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

scientific article published on 01 March 2020

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

scientific article published on 13 March 2012

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

scientific article published in April 2005

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

scientific article published on 29 March 2015

Emerging epigenetic-modulating therapies in lymphoma

scientific article published on 01 August 2019

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 18 May 2017

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

scientific article published on 27 March 2015

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma ⬇️

scientific article published on March 1, 2012

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

scientific article

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

scientific article

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

scientific article published on 17 July 2020

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

scientific article

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results

scientific article

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 16 March 2013

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

scientific article

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

scientific article

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

scientific article published on 28 February 2019

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

scientific article published on 25 October 2011

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

scientific article

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

scientific article published on 08 July 2014

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

scientific article published on 20 May 2019

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

scientific article

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

scientific article published on 31 March 2015

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

scientific article

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

scientific article

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

scientific article published on 3 May 2018

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

scientific article

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

scientific article

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

scientific article published on 26 April 2011

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

scientific article

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

scientific article

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

scientific article published on 27 July 2015

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

scientific article published on 9 August 2017

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma

scientific article published in June 2007

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

scientific article published on October 2013

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

scientific article

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

scientific article

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

scientific article published on 08 January 2020

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

scientific article published on 22 May 2008

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

scientific article published on 06 January 2014

Paulina is supported by:

About Paulina

Help